Minimally Invasive Treatments for Benign Prostatic Hyperplasia (BPH) 7.01.104
Summary
Excellus BlueCross BlueShield policy 7.01.104 covers minimally invasive BPH treatments, including prostatic urethral lift, water vapor thermal therapy, Aquablation and prostate artery embolization, when symptomatic BPH is present and device-specific criteria are met, and it lists prostate artery embolization as changed from investigational to medically appropriate for specific indications in its October 16, 2025 update. Transperineal laser ablation, the temporary implantable nitinol device (iTIND) and drug-coated balloons such as Optilume are considered investigational. The policy history also records an 08/04/26 policy edit that updated the professional guidelines section to reflect the 2026 AUA update and changed the prostate artery embolization grade from C to B.
Get alerts when payers change rules like this one
We check Excellus BlueCross BlueShield and other payers every day and email you when a change matches your specialty and state.